Research programme: triplex forming oligonucleotide-tomaymycin conjugate - Nanogen
Alternative Names: TFO-PBD conjugate; TFO-tomaymycin conjugateLatest Information Update: 19 Aug 2009
Price :
$50 *
At a glance
- Originator Nanogen
- Class Drug conjugates; Oligonucleotides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Suspended Cancer
Most Recent Events
- 09 Jul 2009 Nanogen completes sale of substantially all of its assets and its subsidiaries, Epoch BioSciences and Nanotronics, to Financiere Elitech and DxCon
- 29 Dec 2004 Epoch Biosciences has been acquired and merged into Nanogen
- 24 Jul 2003 Preclinical development for Cancer in USA (unspecified route)